The role of SLCO1B1 genotyping in lowering cardiovascular risk

Pharmacogenomics. 2021 Jul;22(11):649-656. doi: 10.2217/pgs-2021-0075. Epub 2021 Jul 1.

Authors

Charles A Brunette^{1

2}, Jason L Vassy^{1

3

4

5}

Affiliations

¹ Section of General Internal Medicine, Veterans Affairs Boston Healthcare System, Boston, MA 02130, USA.
² Department of Psychological and Brain Sciences, University of Iowa, Iowa City, IA 52242, USA.
³ Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
⁴ Division of General Internal Medicine and Primary Care, Brigham & Women's Hospital, Boston, MA 02115, USA.
⁵ Population Precision Health, Ariadne Labs, Boston, MA 02215, USA.

PMID: 34196599
DOI: 10.2217/pgs-2021-0075

No abstract available

Keywords: SAMS; SLCO1B1; adverse effects; cardiovascular disease; myopathy; pharmacogenetics; rhabdomyolysis; shared decision-making; statin.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Cardiovascular Diseases / drug therapy
Cardiovascular Diseases / genetics*
Decision Making, Shared
Genotype*
Heart Disease Risk Factors*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Liver-Specific Organic Anion Transporter 1 / genetics*
Pharmacogenomic Testing / methods*
Pharmacogenomic Testing / trends

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Liver-Specific Organic Anion Transporter 1
SLCO1B1 protein, human